Company: PRME
Filing Date: 2025-07-14
Form Type: DEF 14A
Source: 0001193125-25-158716
Chunk: 19

Company: Prime Medicine, Inc.
Filing Date: 2025-07-14
Form: DEF 14A
Chunk 19
---
, M.D. Ph.D., FRCP                      
 Chief Scientific Officer                               |     |            |   378,073 |     |                | $10.11 |
| Keith Gottesdiener, M.D. (2)                           
 Former President, Chief Executive Officer and Director |     |            |         - |     |                |      - |
| All current executive officers, as a group (5 persons) |     |            | 2,198,328 |     |                |  $8.25 |
| All current non-employee directors, as a group (7      
 persons)                                               |     |            |   958,920 |     |                | $10.67 |
| All current non-executive officer employees, as a      
 group (149 persons)                                    |     |            | 3,900,066 |     |                |  $9.14 |

12

(1) Dr. Reine was appointed Chief Executive Officer and director of the Company,
effective May 19, 2025.

(2) Dr. Gottesdiener resigned as President, Chief Executive Officer and director of the Company, in each
case effective May 18, 2025, and will not be eligible to participate in the Option Repricing.

Interests of Certain Persons in the Option Repricing

In considering the Board’s recommendation with respect to the approval of the Option Repricing, stockholders should be aware
that, as discussed above, certain of our current employees, including our executive officers, and members of the Board hold Eligible Options that will be repriced if the proposal is approved at the Special Meeting. The Board acknowledges that
approval of this proposal may benefit our employees, directors, and their respective successors.

Accounting Treatment of the Option Repricing

We have adopted the provisions of Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“FASB ASC Topic
718”) regarding accounting for share-based payments. Under FASB ASC Topic 718, we will recognize the original grant date fair value plus the incremental fair value resulting from the modification as compensation. The incremental compensation
cost will be measured as the excess, if any, of the fair value of the repriced Eligible Options immediately following the Option Repricing over the fair value of the Eligible Options immediately prior to the Option Repricing.

Certain U.S. Federal Income Tax Consequences

The following is a general summary as of this date of the federal income tax consequences to us and to U.S. participants for